Nathan Dean, MD
Pulmonary Disease · Salt Lake City, UTNPI 1063437770
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Biofire Diagnostics, LLC at 46.8% of the total. Reporting peaked in 2021 at $2,425 and has fallen 95.4% since, to $112 in 2025.
Across 16 payments — averaging $173.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biofire Diagnostics, LLC$1K
- Merck$1K
- Mannkind Corporation$130
- Alcresta Therapeutics, Inc.$49
- Baxter Healthcare$48
- AstraZeneca$25
- plus $99 from 5 others
Across 21 payments — averaging $141.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$3K
What the payments were for
- Consulting fees$1,12541%
- Speaking & faculty fees$1,30047%
- Food & beverage$32012%
- Education$311%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biofire Diagnostics, LLC | 1 | $1,300 |
| Merck | 1 | $1,125 |
| Mannkind Corporation | 1 | $130 |
| Alcresta Therapeutics, Inc. | 1 | $49 |
| Baxter Healthcare | 2 | $48 |
| AstraZeneca | 1 | $25 |
| Electromed, Inc. | 5 | $23 |
| Viatris Specialty LLC | 1 | $23 |
| Sanofi | 1 | $22 |
| Insmed, Inc. | 1 | $17 |
| Chiesi USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Film Array$1,300
- AFREZZA$130
How this compares
$2,776 in reported general payments places this provider in the 70th percentile of 101 pulmonary disease providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $16,462 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $9,187 |
| Qvar RedihalerBeclomethasone Dipropionate | 21 | $5,875 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 37 | $5,361 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $5,133 |
| Linezolid | 22 | $4,277 |
| Ethambutol Hcl | 63 | $3,185 |
| Azithromycin | 94 | $1,447 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 41 | $1,230 |
| Rifampin | 21 | $1,027 |
| Prednisone | 37 | $267 |
| Amoxicillin | 16 | $226 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $192 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $164 |
| Ciprofloxacin Hcl | 12 | $136 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Salt Lake City
- Mary ScholandSalt Lake City$325K
- Chakravarthy ReddySalt Lake City$82K
- James PearlSalt Lake City$69K
- Jefferson ChambersSalt Lake City$57K
- Lara HardmanSalt Lake City$37K
- Charles ElliottSalt Lake City$12K
- Jacqueline ChoaSalt Lake City$9K
- Ann JefferdsSalt Lake City$9K
- Erin BlackstockSalt Lake City$7K
- Michael BourneSalt Lake City$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.